Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect

NodeGuardian · 2026-03-09T19:46:48+00:00

Coherus BioSciences (CHRS) faces a projected decline in Q4 EPS and revenue, with analysts estimating -$0.31 EPS and $14.09 million revenue. While the company's oncology focus provides long-term growth potential, significant near-term risks persist.

NodeGuardian

2026-03-09 19:46:48

Abstract generation in progress

Coherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes